Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NTRK3
REST API REST API
Homo sapiens
NTRK3 is differentially expressed in 306 experiments: 196 organism parts: kidney, prostate, ... (194 more);, 228 disease states: normal, glioblastoma, ... (226 more);, 97 cell types 304 cell lines 40 compound treatments and 81 other conditions.
Synonyms TRKC
Orthologs ENSBTAG00000011213 (Bos taurus)   Ntrk3 (Rattus norvegicus)   Ntrk3 (Mus musculus)   NTRK3 (2 of 2) (Danio rerio)   F1P2W0_CHICK (Gallus gallus)   ntrk3a (Danio rerio)   sev (Drosophila melanogaster)   LOC100487541 (Xenopus laevis)   NTRK3 (Canis familiaris)   ENSBTAG00000047543 (Bos taurus)   (Compare orthologs)
Gene Ontology Term plasma membrane, protein binding, cytoplasm, membrane, Golgi membrane, response to stress, protein tyrosine kinase activity, transmembrane receptor protein tyrosine kinase signaling pathway, membrane fraction, cell differentiation, ATP binding, transferase activity, transferring phosphorus-containing groups, multicellular organismal development, integral to plasma membrane, response to axon injury, receptor activity, nucleotide binding, protein serine/threonine kinase activity, transmembrane receptor protein tyrosine kinase activity, nervous system development, response to ethanol, protein kinase activity, neuron migration, neurotrophin binding, response to corticosterone stimulus, cellular response to retinoic acid, mechanoreceptor differentiation, cochlea development, negative regulation of astrocyte differentiation, neurotrophin receptor activity, negative regulation of cell death, positive regulation of axon extension involved in regeneration, neuron fate specification, protein autophosphorylation, protein phosphorylation, modulation by virus of host transcription
InterPro Term Cys-rich_flank_reg_C, Ig_sub, LRR-contain_N, Immunoglobulin, Prot_kinase_cat_dom, Ig-like, Ig_I-set, Tyr_kin_neurotrophic_rcpt_3, Tyr_kinase_NGF_rcpt, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession Q8WWU8, Q96CY4, A9X3Y2, Q16288, O95192, B7Z7U4, E7EMI7, E9PG56
Search EB-eye ENSG00000140538
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, ... (33 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (34 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
AGS
2
E-GEOD-15460, E-MTAB-37
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
A549
2
E-GEOD-6013, E-GEOD-3202
U251
2
E-GEOD-20089, E-MTAB-62
primary culture
2
E-GEOD-2450, E-GEOD-1657
298 more value(s).


Cell type

studied in E-MEXP-1121, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-MEXP-66, ... (48 experiments)

Factor Value U/D Experiments
CD8+ T cell
2
E-GEOD-6740, E-MTAB-25
CD34+
2
E-AFMX-5, E-TABM-145
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
adipocyte
1
E-AFMX-5
iPSC derived from hASC using lentiviral reprogramming vector
1
E-GEOD-20033
primary fibroblast
1
E-MEXP-66
91 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-2280, E-GEOD-16363, ... (74 experiments)

Factor Value U/D Experiments
prostate carcinoma
6
E-MTAB-62, E-MEXP-2034, E-MEXP-1327, E-MTAB-37, E-GEOD-96, ... (6 experiments)
lung adenocarcinoma
4
E-MTAB-37, E-MEXP-231, E-MTAB-62, E-GEOD-2514
glioblastoma
2
4
E-GEOD-4290, E-MTAB-37, E-MTAB-62, E-MEXP-567, E-GEOD-6014, ... (6 experiments)
gastric carcinoma
2
E-GEOD-15460, E-MTAB-37
adenocarcinoma
2
E-MTAB-62, E-MTAB-37
alveolar rhabdomyosarcoma
2
E-MTAB-62, E-MEXP-121
222 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-5258, E-GEOD-15205, E-GEOD-697, E-GEOD-3720, ... (22 experiments)

Factor Value U/D Experiments
placebo
2
E-MEXP-1327, E-MEXP-1335
none
3
4
E-GEOD-5824, E-GEOD-412, E-GEOD-7307, E-GEOD-2803, E-GEOD-697, ... (7 experiments)
TGF
1
E-GEOD-15205
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
control - IL-1b
1
E-GEOD-7216
phorbol 12-myristate 13-acetate + ionomycin
1
E-GEOD-3720
34 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-21653, E-GEOD-4922

Factor Value U/D Experiments
38 years
1
1
E-GEOD-4922
44
2
1
E-GEOD-21653
38
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-21374, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-MTAB-69, E-GEOD-22148, ... (8 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, ... (6 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-22056, E-GEOD-2466, E-GEOD-17476, E-MEXP-421, ... (12 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-20540, E-MEXP-1446, E-GEOD-9764, E-GEOD-10315, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-TABM-26, E-MEXP-1648, ... (36 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056, E-GEOD-12662, E-GEOD-7179

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-18791

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400

Sex
studied in E-GEOD-2466, E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19136, E-GEOD-13818

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-4922, E-TABM-147 ... (5 experiments)

Tumor size
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.408 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM